Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
Status:
Recruiting
Trial end date:
2022-09-20
Target enrollment:
Participant gender:
Summary
Objectives: To compare the efficacy and safety in childhood and adolescent patients (<20
years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b
vs. Interferon Alfa.
Study Design: A prospective, open-label, nonrandomized, single-center clinical trial